Effect of Atorvastatin in treatment of COVID-19 infection

Evaluating the efficacy of Atorvastatin in clinical improvement, prognosis and hospitalization course in patients with COVID-19 infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200413047062N1

Enrollment

Registered

2020-05-04

Start date

2020-04-13

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 infection. COVID-19 has been confirmed by laboratory testing

Interventions

Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation + Atorvastatin 20 mg daily for full course of therapy. Intervention 2: Control group: Only national co

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients age over 18 years Hospitalized with diagnosis of COVID-19 infection

Exclusion criteria

Exclusion criteria: Pregnancy Lactation History of hypersensitivity reaction to atorvastatin, Liver dysfunction (Liver enzymes > 3 ULN or bilirubin >2 ULN or history of liver failure) Renal failure (eGFR < 30ml/min), History of major side effects with statins (such as liver toxicity, rhabdomyolysis) Patients are receiving other drugs which have major interaction (such as Gemfibrozil, cyclosporine, amiodarone, itraconazole, variconazole, clarithromycin) LDL Level below than 40 mg/dl Involvement in another clinical study

Design outcomes

Primary

Measure	Time frame
Time to clinical improvement (TTIC). Timepoint: Daily. Method of measurement: Based on clinical findings such as fever, respiratory rate, percentage of oxygen saturation, cough.;Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Adverse effects. Timepoint: Daily. Method of measurement: Interview and patient's record.;Clinical outcome (cure or death). Timepoint: End of the treatment. Method of measurement: Patient's record.	—

Measure

Time frame

Time to clinical improvement (TTIC). Timepoint: Daily. Method of measurement: Based on clinical findings such as fever, respiratory rate, percentage of oxygen saturation, cough.;Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Adverse effects. Timepoint: Daily. Method of measurement: Interview and patient's record.;Clinical outcome (cure or death). Timepoint: End of the treatment. Method of measurement: Patient's record.

—

Secondary

Measure	Time frame
Need for ICU admission. Timepoint: Daily. Method of measurement: Patient's record.;Need for Mechanical ventilation. Timepoint: Daily. Method of measurement: Interview and patient's record.;Change in radiologic findings. Timepoint: End of the treatment. Method of measurement: Patient's record.;The change in inflammatory markers. Timepoint: daily. Method of measurement: Patient's record.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Moezi

Islamic Azad University

Hmoezi@iautmu.ac.ir+98 21 2200 6660

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026